Genocea Biosciences, Inc. has entered into an R&D collaboration and option agreement with Janssen Biotech, Inc. to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in the context of vaccine therapies for cancer. The agreement was facilitated by Johnson & Johnson Innovation. Under the collaboration, Genocea will use its clinically validated ATLAS™ platform to characterize Janssen-identified antigens as well as assess approaches that could mitigate the impact of Inhibigens.

Genocea will receive a technology access fee and full R&D funding for its work under the collaboration. The agreement includes an option for Janssen to negotiate a future strategic partnership to develop non-personalized vaccine products using Genocea's ATLAS platform and expertise on Inhibigens.